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Despite clear epidemiological and genetic evidence for X-linked prostate cancer risk, all prostate cancer
genes identified are autosomal. Here, we report somatic inactivating mutations and deletion of the X-linked
FOXP3 gene residing at Xp11.23 in human prostate cancer. Lineage-specific ablation of FoxP3 in the mouse
prostate epithelial cells leads to prostate hyperplasia and prostate intraepithelial neoplasia. In both normal
and malignant prostate tissues, FOXP3 is both necessary and sufficient to transcriptionally repress cMYC,
the most commonly overexpressed oncogene in prostate cancer as well as among the aggregates of other
cancers. FOXP3 is an X-linked prostate tumor suppressor in themale. Because themale has only one X chro-
mosome, our data represent a paradigm of ‘‘single genetic hit’’ inactivation-mediated carcinogenesis.INTRODUCTION
Genetic lesions of several autosomal tumor suppressor genes,
including PTEN (Sansal and Sellers, 2004; Suzuki et al., 1998),
NKX3.1 (Emmert-Buck et al., 1995; Vocke et al., 1996), and
KLF6 (Bar-Shira et al., 2006; Narla et al., 2005; Narla et al.,
2001), have been implicated in the molecular pathogenesis of
prostate cancer. In addition, epidemiological studies have sug-
gested a role for X-linked genes that control the susceptibility
to prostate cancer (Monroe et al., 1995). Although two loci, one
in Xp11.22 (Gudmundsson et al., 2008) and one in Xq27-28 (Xu
et al., 1998), have been implicated, the genes in these regions
have not been identified. X-linked tumor suppressor genes are
of particular interest because the majority of X-linked genes
are dose compensated, making a single hit sufficient to inacti-
vate their functions (Spatz et al., 2004). Although we and others
have reported X-linked tumor suppressor genes, WTX1 (Rivera
et al., 2007) and FOXP3 (residing at Xp11.23) (Zuo et al.,
2007b) in female cancer patients, none have been identified for
cancer in male patients.336 Cancer Cell 16, 336–346, October 6, 2009 ª2009 Elsevier Inc.In addition to inactivation of tumor suppressors, activation of
proto-oncogenes also play a critical role in carcinogenesis.
Among them, c-MYC (hereby called MYC) is known as one of
themostcommonlyoverexpressedoncogenes.MYCoverexpres-
sion occurs in more than 30% of all human cancer cases studied
(Grandori et al., 2000). However, the mechanism by which MYC
transcription is increased in the prostate cancer remains unclear.
InBurkitt’s lymphoma, theMYC locus is translocated intoaconsti-
tutively active Ig locus (Dalla-Favera et al., 1982; Taubet al., 1982),
which was found to lead to its transcriptional activation (Erikson
et al., 1983). In lung cancer, high levels of gene amplification of
the MYC locus have been documented (Wong et al., 1986),
although such amplification occurred considerably less frequently
than overexpression ofMYCmRNA (Takahashi et al., 1989). Like-
wise, in breast and prostate cancer, upregulation of MYC mRNA
was substantially more frequent than amplification of the MYC
gene (Bieche et al., 1999; Jenkins et al., 1997; Latil et al., 2000).
BecauseMYC has been shown to be a target of b-catenin activa-
tion (He et al., 1998;Sansomet al., 2007), an appealing hypothesis
is that MYC upregulation may be a manifestation of aberrant WntSIGNIFICANCE
The study describes two significant advances. First, we demonstrate FOXP3 as an X-linked tumor suppressor gene in the
male in both human and mice. Because the male has only one X chromosome, our work represents a compelling exception
to the widely accepted ‘‘two hit’’ theory for inactivation of tumor suppressor genes. Second, our work demonstrates that
FOXP3 is a major transcriptional repressor of c-MYC oncogene in the prostate. FOXP3 inactivation is necessary and suffi-
cient for c-MYC overexpression, which is critical for molecular pathogenesis of prostate cancer.
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and Dang, 1999). However, a general significance of b-catenin-
mediatedMYC upregulation remains to be demonstrated (Kolligs
et al., 1999; Bommer and Fearon, 2007). Therefore, for the ma-
jority of cancer types, the genetic change involved in the aberrant
MYC expression remained to be defined.
MYC overexpression in benign prostate hyperplasia and pros-
tate cancer was documented over 20 years ago (Fleming et al.,
1986). Ectopic expressionofMYCcauseshyperplasia of prostate
tissue (Thompson et al., 1989). Further studiesdemonstrated that
Myc and Ras in combination could induce prostate cancer in
mice (Lu et al., 1992). More recently, gene expression profiling
of a mouse prostate cancer model induced by Myc transgene
indicated similarity with human prostate cancer (Ellwood-Yen
et al., 2003). Consistent with a role for MYC in the pathogenesis
of prostate cancer, several whole genome scanning studies
have strongly implicated a region 260 kb telomeric to the MYC
gene in susceptibility to prostate cancer (Amundadottir et al.,
2006; Gudmundsson et al., 2007; Haiman et al., 2007a; Haiman
et al., 2007b; Witte, 2007; Yeager et al., 2007).
Here, we investigated whether the FOXP3 gene is frequently
inactivated in prostate cancer samples by deletion and somatic
mutation. Moreover, we determined the significance of such
inactivation by growth inhibition of normal and cancerous pros-
tate cell lines and by identification of FOXP3 targets. The impact
of prostate-specific ablation of the FoxP3 gene in the mouse
was also tested.
RESULTS
Somatic Inactivation of the FOXP3 Locus in Human
Prostate Cancer Samples
We first evaluated the expression of FOXP3 in both normal and
malignant prostate tissues by immunohistochemistry. Although
Figure 1. Downregulation of FOXP3 in Pros-
tate Cancer
(A and B) Loss of FOXP3 expression in prostate
cancer samples. Data show IHC data for FOXP3
expression in benign versus cancerous tissue in
either thawed frozen tissues after short-term
formalin fixation (A) or TMA samples after an
extended antigen retrieval (B), using monoclonal
anti-FOXP3 mAb (236A/E7, 1:100). Statistical
significance was analyzed by chi-square tests.
(C) Downregulation of FOXP3 transcripts in pri-
mary cancer tissue in comparison to normal pros-
tate tissue from the same patients (p value by a
Wilcoxon two-sample test). Data show real-time
PCR quantitation of microdissection samples
from 18 cases. The relative amounts are ex-
pressed as a percentage of GAPDH.
our previous studies have demonstrated
the expression of FoxP3 in the mouse
prostate using an affinity-purified anti-
FoxP3 peptide antibody (Chen et al.,
2008), the FOXP3 expression was not
reported in either normal or malignant
human prostate tissues by immunohisto-
chemistry (IHC), even though FOXP3 expression on infiltrating
regulatory T cells was clearly detectable (Fox et al., 2007; Ronca-
dor et al., 2005). As the master regulator of regulatory T cells,
FoxP3 is expressed there at levels comparable to those of
housekeeping genes, such as GAPDH and HPRT (Fontenot
et al., 2003; Hori et al., 2003). Because FoxP3 expression in pros-
tate tissue is approximately 100-fold lower than what was found
in regulatory T cells (Chen et al., 2008), we reasoned that the lack
of detectable FOXP3 in normal prostate tissuemay be caused by
low sensitivity of staining and/or tissue processing conditions.
Therefore, we first fixed the frozen tissues in 10% formalin for
8–12 hr and screened a large panel of commercially available
anti-FOXP3 antibodies for their reactivity to endogenous
FOXP3 in epithelial tissues. A shown in Figure S1 (available
with this article online), anti-FOXP3mAb stained prostate epithe-
lial uniformly. However, compared with infiltrating lymphocytes,
the level of FOXP3 is considerably lower (Figure S2).
As summarized in Table S1, four commercially available mAbs
gave uniform staining of FOXP3 in normal prostate epithelia. The
fact that multiple anti-FOXP3 mAbs reacted to FOXP3 demon-
strated that FOXP3 is expressed at significant levels in normal
prostate tissue. Among them, two (hFOXY and 236A/E7) were
also tested and found to react specifically with FOXP3 protein
in western blot of lysates made from immortalized mammary
epithelial cell line MCF-10A. The specificity of the reactivity to
human FOXP3 was further confirmed by comparing reactivity
of scrambled and FOXP3 ShRNA-transduced normal epithelial
cell line MCF10A by western blot and by IHC (Figure S3).
Using the uniform fixation and processing conditions, we eval-
uated the expression of FOXP3 in 85 cases of normal and 92
cases of cancer tissues. As shown in Figure 1A, immunohisto-
chemistry with anti-FOXP3 mAb detected nuclear FOXP3
staining in 100% of the normal prostate tissues tested. In con-
trast, only 31.5% of the prostate cancer samples show nuclearCancer Cell 16, 336–346, October 6, 2009 ª2009 Elsevier Inc. 337
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fixation conditions in preparing samples for tissue microarrays,
the FOXP3 protein was generally difficult to detect by IHC, unless
high concentrations of antibodies were used (data not shown).
Using an extended antigen retrieval (37C overnight following
heating in microwave oven), we have obtained clear, albeit
somewhat weaker, staining from tissue microarray samples
using low concentrations of anti-FOXP3 mAb. However, 13%
of normal tissues were not stained, presumably because of
harsher fixation conditions. As shown in Figure 1B, a significant
reduction was observed among prostate cancer tissues. Fur-
thermore, when the samples with prostate epithelial neoplasia
(PIN) were compared with normal tissues, we observed a statis-
tically significant reduction of FOXP3 expression in PIN (Figures
S4A and S4B). Taken together, our data demonstrated that
FOXP3 downregulation is widespread in prostate cancer and
that such downregulation may have occurred at an early stage
of prostate cancer.
We then usedmicrodissection to obtain benign prostate tissue
and cancer tissues from the same patients and compared the
FOXP3 mRNA levels. Because inflammatory T cells are a major
source of FOXP3 expression, we carefully avoided areas of
inflammation for dissection. After normalizing against the house-
keeping gene, 14 of 18 cases showed 2–10-fold reduction of
FOXP3 mRNA in comparison to the benign tissues (Figure 1C).
Six of the 18 samples contain clearly identifiable PIN lesions.
We therefore microdissected the PIN lesions and compared
the levels of FOXP3mRNA transcript with normal and cancerous
tissues. As shown in Figure S4C, FOXP3 transcript is downregu-
lated in PIN lesion. Thus, reduced FOXP3 expression is wide-
spread among prostate cancer samples, perhaps starting at
early stage of carcinogenesis.
We used fluorescence in situ hybridization (FISH) to determine
FOXP3 gene deletion in the prostate cancer tissue. As shown in
Figure 2 and Table S2, 23 (13.9%) of 165 samples tested showed
adeletionof theFOXP3gene.Among them,18of the23caseshad
a single copy of the X chromosome. However, 5 of the 23 cases
showed an increase in the number of X chromosomes. Interest-
ingly, in cells with X polysomy and FOXP3 deletion, the deletion
was complete in all X chromosomes. Thus, X chromosome dupli-
cations in cancer tissues likely occurred after deletion of FOXP3.
Figure 2. Deletion of a FOXP3 Among Prostate
Cancer Samples
TMA and frozen samples were hybridized to the FOXP3
(red) or X chromosome probe (green). Of 165 cases with
informative FISH data, a total of 23 cases showed
FOXP3 deletion.
To determine whether FOXP3 was somati-
cally mutated in primary prostate cancer
samples, we isolated cancerous and normal
prostate tissues from the same patients and
compared the DNA from exons and some
exon-intron junctions. A summary of the data
is shown in Figure 3A and a representative chro-
matogram is shown in Figure 3B, with other
chromatograms provided in Figure S5. Our
sequencing analyses demonstrate single base-pair changes in
5 of 20 samples tested (Table S3). Among them, four were
missense mutations, whereas one caused a change in intron 6.
One of the missense mutation (K227R) was also reported in the
breast cancer (Zuo et al., 2007b). The tumors with the intron 6
mutation showed reduced expression of FOXP3 (Figure 3C).
Among the five samples that contain FOXP3 mutation in cancer
tissue, two contained identifiable PIN lesions. We therefore mi-
crodissected the PIN lesion to determine whether the same
mutation can be found. As shown in Figure S5, both samples
had the same mutations in PIN and cancerous tissues.
To substantiate tumor suppressor activity of FOXP3, we trans-
fected FOXP3 cDNA into prostate cancer cell lines PC3, LNCaP,
and Du145. Our data demonstrated strong growth inhibition by
FOXP3 (Figures S6 and S7). Importantly, although vector-trans-
fected LNCaP responds to hormone 5a-dihydrotestosterone
(5a-DHT), FOXP3 expression abrogated its stimulation by the
hormone (Figure S7). The growth inhibition by wild-type (WT)
FOXP3 provided an important functional test for the somatic
mutants uncovered from the clinical samples. As shown in
Figure 3D, only WT FOXP3, but none of the missense mutants,
abrogated growth of prostate cancer cell line Du145. Similar
data were obtained with another cell line PC3 (data not shown).
Therefore, the somatic mutations of the FOXP3 are functionally
inactivated.
FOXP3 is a transcriptional regulator that functions by interact-
ing with DNA in the nuclei (Zuo et al., 2007b). As the first step to
understand the mechanism by which the mutations in FOXP3
affect its function, we tagged the FOXP3 protein with the green
fluorescence protein (GFP) at the N terminus and visualized its
intracellular localization by confocal microscopy. As shown in
Figure 3E, three of four somatic mutants disrupted its transloca-
tion into nuclei. To substantiate these observations, we isolated
cytoplasm, nucleoplasm, and chromatin from PC3 transected
with vector control and from WT and somatic FOXP3 mutant
cDNA and determined distribution of FOXP3 by western blot.
As shown in Figure 3F, althoughWT FOXP3 and the V79Amutant
reside in both the nucleoplasm and the chromatin, the over-
whelming majority of the proteins encoded by other three
missense mutants are excluded from the nucleus. Because
these three mutations had a more severe impact on the growth338 Cancer Cell 16, 336–346, October 6, 2009 ª2009 Elsevier Inc.
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appears to be the major mechanism to inactivate the tumor
suppressor function. To confirm that disruption of nuclear local-
ization is sufficient to abrogate growth inhibition by FOXP3, we
used site-directed mutagenesis to inactivate the known nuclear
localization sequence of FOXP3. As shown in Figure S8, muta-
tion in nuclear localization sequence was sufficient to abrogate
growth inhibition by FOXP3.
Prostate-Specific Deletion of FoxP3 Caused
Precancerous Lesions
To test the cell-intrinsic effect of FoxP3 deletion, we crossed the
mice with a floxed FoxP3 locus (diagrammed in Figure 4A) (Fon-
tenot et al., 2005) to a transgenic line that expresses Cre gene
under the probasin promoter (PB-Cre4) (Wu et al., 2001).
Previous studies have demonstrated that this promoter causes
prostate-specific deletion of Floxed genes starting in new-born
Figure 3. Somatic Mutation of FOXP3 Gene
in Prostate Cancer Samples
DNA samples from cancerous and benign tissues
dissected from 20 cases of frozen prostate cancer
tissues were amplified by PCR and sequenced.
The somatic mutants were identified by com-
paring the DNA sequence of normal and can-
cerous tissues from the same patients.
(A) Diagram of the FOXP3 gene showing the posi-
tion of the somatic mutations identified.
(B) A representative chromatogram showingmuta-
tion of FOXP3 in exon 3.
(C) Partial inactivation of the FOXP3 locus in pros-
tate cancer with an intronic mutation. Data shown
are means and SD of relative levels of FOXP3 tran-
scripts, with the levels of normal tissues defined as
1.0. This experiment has been repeated once.
(D) Missense mutations of the FOXP3 gene abro-
gated inhibition of the colony formation of the
prostate cancer cell line Du145 by FOXP3. Data
shown are means and SD of colony numbers in
10 cm dishes (n = 3). The expression of FOXP3 is
presented underneath the bar graph. This experi-
ment has been repeated at least 3 times.
(E) Impact ofmissensemutations on nuclear trans-
location of FOXP3. WT and mutant FOXP3 were
tagged with GFP at the N termini and transfected
into PC3 cell line. After drug selection to remove
untransfected cells, the cells were stained with
DAPI to visualize nuclei. Photos shown aremerged
DAPI and GFP images captured by confocal
microscope.
(F) Cellular localization of WT and mutant FOXP3
as measured by western blot after cellular frac-
tionation. The cellular fractions were subject to
western blot analysis with anti-FOXP3 mAb
(Abcam, ab450) and marker proteins.
mice (Wu et al., 2001). Using microdis-
sected tissue samples of 8–12-week-old
mice, we observed more than 80% dele-
tion of the FoxP3 locus among the micro-
dissected prostate epithelial tissue (Fig-
ure 4B). The FoxP3 mRNA was reduced
by more than 16 fold (Figure 4C). The
less profound reduction in DNA levels likely reflected the fact
that our microdissected samples also contained nonepithelial
cells that do not express FoxP3 (Chen et al., 2008). The reduction
of FoxP3 protein is confirmed by western blot using the lysates
of total prostate (Figure 4D) and immunohistochemistry staining
(Figure 4E). Consistent with the kinetics and levels of the
PB-Cre4 transgene expression (Wu et al., 2001), the deletion is
more complete in the ventral and lateral prostate lobes than in
the anterior and dorsal lobes.
We took several approaches to determine the effect of pros-
tate-specific deletion in the FoxP3 locus. First, we used mag-
netic resonance imaging (MRI) to monitor the prostate size in
the live mice. As shown in Figure 5A, 12–15-week-old mice
with prostate-specific deletion of the FoxP3 locus had signifi-
cant enlargement of the prostate. In comparison to WT, a
5-fold increase in the percentage of Ki67+ proliferating epithelial
cells was observed in the mutant mice (Figure 5B). HistologicalCancer Cell 16, 336–346, October 6, 2009 ª2009 Elsevier Inc. 339
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Prostate
(A) Diagram of the floxed FoxP3 locus and the
position of the primers used to measured the ratio
of deleted versus undeleted alleles.
(B) Efficient deletion of the FoxP3 locus in the
PB4-Cre4+FoxP3flox/y (cKO) but not the PB-Cre4+
FoxP3+/y transgenic mice (p value by an indepen-
dent-samples t test). Data shown are means and
SD of the ratio of product A/product B of DNA iso-
lated from themicrodissected prostate epithelium.
(C) Targeted deletion of the FoxP3 locus caused
dramatic reduction of FoxP3 transcripts in pros-
tate tissue (p value by a Mann-Whitney U test).
The RNA isolated from microdissected prostate
epithelia were quantitated by real-time PCR.
(D) Reduction in FoxP3 expression, as determined
by western blot with anti-FoxP3 mAb (hFOXY).
Data shown are lysates of prostate tissues from
PB-Cre4+FoxP3+/y and PB-Cre4+FoxP3flox/y mice.
(E) Reduction of FoxP3 expression as determined
by immunohistochemistry with a polyclonal rabbit
anti-mouse FoxP3 antibodies (Poly6238). Staining
of ventral prostate lobes is presented. Similar
reduction in FoxP3 expression was also observed
in lateral prostate. Significant, but less complete,
reduction in anterior and dorsal lobes was also
found. Data in (B–D) were obtained from tissues
of 8–12-week-old mice, whereas those in (E)
were obtained from 14–16-week-old mice.examination of the prostate revealed signs of prostate hyper-
plasia as early as 14–16 weeks in five of six mutant mice. At
23–26 weeks old, 4 of 5 mutant mice, but none of the six age-
matched WT mice, exhibited extensive hyperplasia (Figure 5C
and Figure 6A). Early PIN was detectable at 23–26 weeks in
a small fraction of ventral and dorsal prostate lobes with
FoxP3 deletion, characterized by increased layers of epithelial340 Cancer Cell 16, 336–346, October 6, 2009 ª2009 Elsevier Inc.cells and nuclear atypia (Figure 5C and data not shown). By
43–60 weeks, all cKO mice examined had hyperplasia. More-
over, all but 1 of 9 cKO mice exhibited early PIN, including
multiple layers of epithelial cells (Figures 6B and 6C). The epithe-
lial cells in this region had significantly enlarged nuclei, in
comparison to either the single-layered epithelial cells in the
same glandular structure (data not shown) or those in the controlFigure 5. Prostate-Specific Deletion of
FoxP3 in the Prostate Induces Precan-
cerous Lesions
(A) FoxP3 deletion caused enlargement of pros-
tates. The prostates of 12- to 15-week-old, age-
matched WT and condition KO (cKO) mice were
measured by magnetic resonance imaging (MRI)
(p value by an independent-samples t test). The
images of a representative prostate from each
group are shown on the left, whereas the prostate
volumes of individual mice are shown on the right.
(B) FoxP3 deletion led to increased proliferation of
prostate epithelium, using expression of Ki67 as
an indicator of proliferating cells (p value by
a Mann-Whitney U test). Representative mor-
phology and Ki67 staining are shown at the top,
and the percentage of Ki67+ cells among the
epithelial cells are shown at the bottom. At least
five 403 fields for each mouse, at 14–16 weeks
of age, were counted.
(C) Incidence of prostate hyperplasia (HP) and
prostatic intraepithelial neoplasia (PIN) in cKO
(PB-Cre4+FoxP3flox/y) and in WT (combining both
PB-Cre4+FoxP3+/y and PB-Cre4FoxP3flox/y). The
statistical significance was determined by a log-
rank test.
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epithelia formed both papillary and tufting (Figure 6C) patterns.
Under high power, the luminal epithelial cells in these areas ap-
peared transformed, as demonstrated by enlargement of nuclei
and more-active nucleoli (Figure 6C). In most mice, multiple
PINs were found in the anterior, ventral, and lateral prostate
lobes, although the lesions are all focal in nature. All WT pros-
tates have normal morphology through the course of the study.
Therefore, targeted mutation of the FoxP3 gene in prostate
Figure 6. Histology Data of Hyperplasia and Early PIN
(A) Representative H&E staining of hyperplastic lesions in 24-week-old cKO
ventral prostate sections. A 26-week-oldWT (PB-Cre4+FoxP3+/y) ventral pros-
tate image is shown for comparison.
(B) A representative early PIN lesion in ventral prostate of a 43-week-old cKO
mouse. The image of an age-matched (PB-Cre4+FoxP3+/y) ventral prostate
was included for comparison. Low (upper panels) and high (middle panels)
power images are presented. The sizes of nuclei were determined by Scion
Image software (Scion Corporation, Frederick, Maryland).
(C) A PIN lesion in ventral prostate of a 60-week-old cKO mouse, showing the
papillary and tufting. A high-power imagine showing enlarged nuclei and active
nucleoli is presented in the lower panel.tissue is sufficient to initiate the process of prostate cancer
development.
FOXP3 Is Necessary and Sufficient to Repress
Expression of MYC
MYC is overexpressed in 80% of the prostate cancer samples
starting as early as benign hyperplasia (Fleming et al., 1986).
However, the mechanism by which MYC transcription is
increased remains unclear. We tested whether MYC upregula-
tion correlates with downregulation of the FOXP3 transcripts.
We measured the levels of the mRNA transcripts from microdis-
sected cancerous and benign tissues from 18 patients by real-
time PCR. We normalized the transcript levels in cancer tissue
against the normal epithelia from the same patients in order to
avoid differential RNA degradation under different sample pro-
curement conditions. We observed an increased MYC expres-
sion in 15 of 18 cases. Importantly, a significant correlation
was observed between FOXP3 downregulation and MYC over-
expression among malignant tumor samples (Figure 7A). When
the levels of normal and cancer tissues were compared sepa-
rately, a negative correlation between FOXP3 and MYC levels
was found in cancer but not normal samples (Figure S9). To
test the relevance of this observation in human prostate cells,
we tested the effect of the FOXP3 shRNA on MYC expression
in early passage primary human prostate epithelial cells. Normal
prostate cell culture grew slowly and expressed low levels of
MYC. ShRNA silencing increased the growth rate of the culture
(Figure S10). As shown in Figure 7B, FOXP3 shRNA caused
amajor reduction in the expression of FOXP3mRNA and protein.
Correspondingly, the levels ofMYC transcripts and protein were
significantly elevated by FOXP3 shRNA. To test whether the
correlation could be causative and independent of cancer devel-
opment in vivo, we microdissected normal WT and FoxP3-
deleted prostate tissues and compared theMyc transcript levels.
As shown in Figure 7C, prostate deletion of the FOXP3 locus
caused a more than 4-fold increase in Myc mRNA. Moreover,
the increased transcript levels were also reflected in elevation
of the Myc protein in the nuclei (Figure 7D). These data demon-
strated that FoxP3 is a necessary repressor for the Myc locus.
To test whether ectopic expression of FOXP3 is sufficient to
repress MYC, we transfected two prostate cancer cell lines with
FOXP3. As shown in Figure 7E, FOXP3 transfection almost
completely abrogated the expression of MYC in both cell lines.
To determine whether the growth inhibition was mediated
by repression ofMYC, we cotransfected FOXP3 withMYC cDNA
into Du145 cells. The cells were transfected with either pcDNA6-
blasticidin vector or MYC cDNA (comprising the entire coding
region but no untranslated regions) and either the pEF1-G418
vector orFOXP3 cDNA.As shown in Figure 7F, ectopic expression
of MYC overcame FOXP3-mediated tumor suppression. These
data demonstrated thatMYC repression explains the growth inhi-
bition of FOXP3, at least for established prostate cancer cell line.
Molecular Mechanisms for FOXP3-Mediated MYC
Repression and for Somatic Inactivation of FOXP3
To understand the mechanism by which FOXP3 repressesMYC,
we used ChIP to identify the site of FOXP3 binding in the MYC
promoter. As shown in Figure 8A, quantitative PCR analysis indi-
cated that, despite the abundance of forkhead binding sites,Cancer Cell 16, 336–346, October 6, 2009 ª2009 Elsevier Inc. 341
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Sufficient to Repress the MYC Oncogene
(A) Inverse correlation between FOXP3 and MYC
expression in primary prostate cancer tissues.
Statistical significance was observed by using
a linear regression model. Data shown are ratio
of transcript levels of tumor over benign prostate
tissues from the same patients after they were
normalized to housekeeping genes. Data from
quantitative real-time PCR in 18 cases are pre-
sented.
(B) ShRNA silencing of FOXP3 resulted in upregu-
lation of MYC expression in primary HPEC. Early
passage HPEC were infected with retroviral vector
expressing either control or FOXP3 shRNA. The
uninfected cells were removed by drug selection.
At 1 week after infection, the levels of FOXP3 or
MYC mRNA were quantitated by real-time PCR.
The levels were normalized against GAPDH, and
those in the control group were defined as 1.0.
Data shown are the means and SD of triplicates
and were repeated two times. The lower panel
shows the levels of FOXP3 and MYC proteins as
revealed by western blot.
(C) Targeted deletion of the FoxP3 locus caused
elevation of theMyc transcripts in mouse prostate
tissue (p value by a Mann-Whitney U test). The
RNA isolated from microdissected prostate
epithelia, from 8- to 12-week-old mice, was quan-
titated by real-time PCR. Data shown are relative
levels of Myc mRNA, expressed as a percentage
of Hprt mRNA.
(D) Immunohistochemistry analysis of Myc expression in PB-Cre4+ and cKO prostate. Data shown are images from dorsal lobes. A comparable elevation was
observed in all four lobes.
(E) Ectopic expression of FOXP3 into prostate cancer cell lines repressed MYC expression. PC3 and Du145 cell lines were transfected with V5-tagged FOXP3.
After removal of uninfected cells by drug selection, the total cell lysates were analyzed for expression of FOXP3-V5, MYC, and b-actin as loading control.
(F) Transfection withMYC cDNA prevents FOXP3-mediated growth inhibition. In addition to either control or FOXP3 cDNA, the tumor cell lines were infected with
either control vector orMYC plasmid. A representative photograph of cell growth after crystal violet staining is shown on the left; representative data from one of
four experiments using the Du145 cell line are presented in the right. Data shown are means and SD of colony numbers in 6 cm dishes (n = 3). The levels of FOXP3
and MYC proteins are shown underneath the bar graph. Similar rescue was also found when the PC3 cell line was used (data not shown).a strong binding of FOXP3 centered around0.2 kb 50 of the first
transcription-starting site (TSS-P1). To test the significance of
this site for the repression, we performed a deletional analysis
to map the region that conveys susceptibility to FOXP3 repres-
sion. As shown in Figure 8B, little repression by FOXP3 can be
observed when the reporter was truncated before the forkead
binding site at the 0.2 kb region (F1–F2). Strong inhibition
was observed when the binding motif was included (F3–F5).
Additional sequences did not increase the efficiency of repres-
sion. Sequence alignment revealed a conserved forkhead-
binding site surrounding the promoter region with the highest
ChIP signal (Figure 8C). When the site was either deleted or
mutated, the repression was completely abrogated (Figure 8C).
These data demonstrated that FOXP3 repressesMYC promoter
activity by interacting with the forkhead motif at the0.2 kb 50 of
the MYC TSS.
To test whether somatic mutations of FOXP3 affect MYC
repression, we transfected WT and mutant FOXP3 cDNA into
the Du145 prostate cancer cell line in conjunction with the
MYC promoter. Despite similar levels of FOXP3 protein, somatic
mutations substantially reduced MYC repression (Figure 8D).
Because three of the four mutants failed to localize into the nuclei
(Figures 8E and 8F), we tested the remaining mutant for its ability342 Cancer Cell 16, 336–346, October 6, 2009 ª2009 Elsevier Inc.to bind to the MYC promoter. As shown in Figure 8E, the V79A
mutation significantly reduced the binding of FOXP3 to the
MYC promoter. Taken together, the data presented in this
section demonstrate that FOXP3 represses MYC expression
by binding the forkhead-binding motif in the promoter. Somatic
mutations uncovered in human prostate cancer abrogated the
MYC repression by either preventing FOXP3’s nuclear localiza-
tion or its binding to a cis-element in the MYC promoter.
DISCUSSION
Molecular pathogenesis of prostate cancer development
includes both upregulation of oncogenes, such as MYC, and
inactivation of tumor suppressor genes, such as autosomal
genes PTEN and NKX3.1. Although X-linked genes have been
implicated by genetic epidemiology and linkage analysis, no
X-linked tumor suppressors have been identified for prostate
cancer. Our study described herein fills amajor gap by identifying
the FOXP3 gene as an X-linked tumor suppressor gene in males.
FOXP3 Is a Tumor Suppressor in Prostate Cancer
We and Rivera et al. have recently reported the involvement of
X-linked tumor suppressorgenes in femalecancerpatients,where
Cancer Cell
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Repression by FOXP3 and Its Inactivation
by Mutations in Cancer
(A) Identification of a FOXP3-binding site in the 50
region of theMYC gene. The top panel is a diagram
of the MYC gene (Bossone et al., 1992), with the
Forkhead consensus motifs and the areas cov-
ered by PCR primers marked. The distances
related to the transcriptional starting site (TSS)
are shown. The lower panel shows the amounts
of DNA precipitated, expressed as a percentage
of input DNA. Data shown were repeated two
times.
(B) FOXP3 repressed the MYC promoter. The top
panel shows a diagram of the MYC locus. The
lower left panel shows the MYC regions included
in the luciferase reporter, whereas the lower right
panel shows the percentage of inhibition of the
promoter activity, expressed as follows: (1 lucif-
erase activity in the presence of FOXP3/luciferase
activity in the absence of FOXP3) 3 100. Data
shown are means of three independent experi-
ments.
(C) Deletion or mutation of the FOXP3-binding
sites abrogated FOXP3-mediated suppression of
the MYC reporter. The top shows the alignment
of human, mouse, and rat MYC, revealing that
the identified FOXP3-binding motif in MYC is in
conserved region. The FOXP3-binding motif is
shown in the box. The F3 WT reporter or those
with either deletion (195 to 189: TGTTTAC) or
mutation (195 to 189: TGTTTAC to AAAAGGG)
of the reporter were transfected into 293T cells in
conjunction with either control or FOXP3-express-
ing vector. The mean luciferase activities in the
absence of FOXP3 cDNA were artificially defined
as 100%.
(D) Somatic mutation of FOXP3 reduced its
repressor activity for the MYC promoter. In the
upper panel, the F3 WT reporters were cotrans-
fected with either vector control or cDNA encoding
WT or mutant FOXP3 into the 293T cell line. At
48 hr after transfection, the lysates were harvested
to measure luciferase activity. Data shown have
been reproduced three times. In the lower panel,
WT or mutant FOXP3 were transfected into the
Du145 cells, and the FOXP3 and MYC protein
expression was analyzed by western blot.
(E) Despite normal nuclear translocation, V79A mutant show reduced binding to the critical cis-element at 0.2 kb region. Sonicated chromatins isolated from
either WT or V79A mutant-transfected Du145 cells were precipitated with either control mouse IgG or mAb specific for FOXP3 (Abcam, ab450). The amounts of
specific DNA were quantitated by real-time PCR using primers corresponding to the 0.2 and +13.5 kb regions. Data shown are means percentage input DNA
and have been reproduced three times. Error bars in this figure indicate SD.the suppressor genes are functionally silenced by a programmed
epigenetic event that occurred in all cells (X-inactivation) and
another lesion such as gene deletion and/or mutation (Rivera
et al., 2007; Zuo et al., 2007b). Here, we describe evidence
that, in the male, the FOXP3 locus is silenced by deletion and
somatic mutation.
Immunohistochemical analysis demonstrated that the nuclear
FOXP3 protein is absent in 68.5% of prostate cancer cases
tested. Thus, in addition to deletion and mutation identified
herein, additional mechanisms, such as epigenetic silencing or
mutations outside the areas analyzed, may also contribute to
lack of FOXP3 expression. In contrast, 100% of benign prostate
samples exhibited clear epithelial expression of nuclear FOXP3.The overwhelming difference strongly suggests a relationship
between FOXP3 downregulation and cancer development.
This hypothesis has been confirmed by the impact of prostate-
specific deletion of the FoxP3 locus. These data, together with
strong growth inhibition andMYC repression by FOXP3, demon-
strate that the FoxP3 gene plays a critical role in suppressing
pathological transformation of the prostate. However, it should
be pointed out that, similar to other tumor suppressors, including
Trp53 (Chen et al., 2005), NKX3.1 (Abdulkadir et al., 2002; Kim
et al., 2002), and Pten (Chen et al., 2005), we have not observed
a full spectrum of prostate cancer during 60 weeks of observa-
tion. Because FoxP3 regulates Myc and because the effect of
transgenic Myc expression can be either hyperplasia (ZhangCancer Cell 16, 336–346, October 6, 2009 ª2009 Elsevier Inc. 343
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prostate cancer (Ellwood-Yen et al., 2003), it is unclear whether
extended observation time or additional factors are needed to
achieve the full spectrum of prostate cancer. The lack of full
carcinogenesis over the observation period makes our model
valuable for dissecting the contribution of other factors, such
as inflammation and aging, in the pathogenesis of prostate
cancer. Nevertheless, the development of prostate hyperplasia
and intraepithelial neoplasia, a widely accepted precancerious
lesion (Tomlins et al., 2006), demonstrates clearly that inactiva-
tion of FOXP3 in prostate cancer patients contributes to prostate
cancer development. It is of interest to note that statistically
significant downregulation of FOXP3 occurred in the PIN lesion
of human samples. Moreover, somatic mutations of FOXP3
were found in both PIN and cancerous lesions. Because deletion
of FoxP3 in the mouse caused early PIN but no cancerous
lesions so far, it is likely that FOXP3 inactivation is an early event
in prostate carcinogenesis. Inactivation of FOXP3will likely work
in concert with additional genetic hits to cause prostate cancer.
FOXP3 exhibits strong growth inhibition of prostate cancer cell
lines, which is attenuated by somatic mutations in prostate can-
cer samples. Therefore, our genetic studies in mice and humans
demonstrated a critical role for FOXP3 as a tumor suppressor
gene for prostate cancer. The presence of a X-linked tumor
suppressor gene as demonstrated in this study revealed a major
exception for the generally accepted two-hit theory of tumor
suppressor genes in cancer development (Knudson, 1971).
Because the FOXP3 resides near a region of a putative pros-
tate cancer susceptibility locus (Gudmundsson et al., 2008),
an interesting issue is whether identification of FOXP3 may
help to explain reported X-linked genetic susceptibility to pros-
tate cancer (Monroe et al., 1995). In our analysis of more than
100 probands with familiar prostate cancer, we have so far iden-
tified no germline mutation in the coding region of FOXP3 (data
not shown). Given the early onset of lethal autoimmune diseases
associated with inactivating mutation of FOXP3 (Bennett et al.,
2001; Chatila et al., 2000; Wildin et al., 2001), it is unlikely that in-
activating germline mutation of the FOXP3 gene can be found in
prostate cancer patients. Additional analyses are needed to
determine whether the FOXP3 polymorphisms affect suscepti-
bility to prostate cancer.
FOXP3 as a Transcriptional Repressor of Oncogene
MYC
MYC is arguably the most upregulated oncogene in human
cancer, because overexpression has been observed in as
many as 30% of all human cancer cases. Our results show
frequent overexpression of MYC mRNA in prostate cancers, in
comparison to adjacent normal epithelia. Although it is clear
that a mutation of the APC gene resulted in upregulation of
MYC and althoughMYC is essential for the development of colon
cancer associated with APC mutation (He et al., 1998; Sansom
et al., 2007), APC mutation is rare in prostate cancers thus
cannot explain a MYC overexpression in prostate cancer. Like-
wise, although MYC overexpression has been observed in all
stages of prostate cancer, a low level of gene amplification is
observed only in late stages of prostate cancer (Jenkins et al.,
1997; Latil et al., 2000). A similar disparity can be observed in344 Cancer Cell 16, 336–346, October 6, 2009 ª2009 Elsevier Inc.other tumor types, including breast and lung cancer (Takahashi
et al., 1989; Bieche et al., 1999).
Our data presented here provide strong evidence that FOXP3-
mediated repression ofMYC is necessary to controlMYC levels
in normal prostate epithelial cells and explains much of the wide-
spread overexpression of MYC in prostate cancer. Because
transgenic expression of Myc resulted in the development of
prostate cancer with genetic profiles similar to those in human
prostate cancer (Ellwood-Yen et al., 2003), disruption of the
MYC regulator FOXP3, as documented here, likely plays a criti-
cal role for molecular pathogenesis of human prostate cancer.
Nevertheless, using expression array analysis, we have uncov-
ered a large array of genes that are either up- or downregulated
by ectopic expression of FOXP3. Notably, the genes involved in
cancer are the most affected group (Figure S11). Therefore,
much like what was observed in breast cancer, FOXP3 will likely
suppress development of prostate cancer by targeting multiple
genes, including both tumor suppressor and oncogenes (Liu
et al., 2009; Zuo et al., 2007a; Zuo et al., 2007b).
EXPERIMENTAL PROCEDURES
Prostate Cancer Samples
Three sources of prostate tissue samples were used for this study. Frozen
tissues were obtained from the Prostate Cancer Tissue Bank of Ohio State
University with no patient identification information. Tissue microarray
samples came from the University of Michigan, Biomax (US Biomax, Inc.,
Rockville, MD), and Target Biotech (Target Biotech, Inc., Thurmont, MD). All
human studies have been approved by the institutional review board of Ohio
State University and University of Michigan.
Experimental Animals
Transgenic mice PB-Cre4 expressing the Cre cDNA under the control of the
probasin promoter have been described elsewhere (Wu et al., 2001) and were
obtained from the National Cancer Institute Mouse Model Deposit. Mice with
Floxed FoxP3 locus (Fontenot et al., 2005) were provided by Dr. Alexander Ru-
densky. Male PB-Cre4+/ mice were crossed to female FoxP3flox/flox or FoxP3-
flox/+ mice. The male F1 mice of given genotypes were used in the study. The
pathological evaluation was performed according the Bar Harbor meeting
guideline (Shappell et al., 2004). All animal studies have been approved by
the University of Michigan Animal User and Carer Committee.
Cell Cultures and Antibodies
Human prostate epithelial cells (HPECs) were purchased from Lonza Group
Ltd. (Switzerland) and cultured with medium from the same vendor. Early
passage HPECswere infected with retrovirus expressing either control shRNA
or FOXP3 shRNA vector. Two FOXP3 short hairpin RNA (shRNA) constructs
are FOXP3-993-shRNA and FOXP3-1355-shRNA (GenBank accession
number NM_014009). Oligonucleotides encoding small interfering RNA
(siRNA) directed against FOXP3 are 50-GCTTCATCTGTGGCATCATCC-30 for
FOXP3-993-shRNA (993–1013 nucleotides from TSS) and 50-GAGTCTGC
ACAAGTGCTTTGT-30 for FOXP3-1355-shRNA (1355–1375 from TSS). The
selected shRNA oligonucleotides were cloned into pSIREN-RetroQ vectors
(Clontech, Mountain View, CA) to generate siRNA according tomanufacturer’s
protocol. Prostate cancer cell lines Du145 and PC3 were obtained from the
American Type Culture Collection (ATCC, Rockville, MD). Antibodies specific
for the following targets were used for the study: cMyc (Santa Cruz Biotech-
nology, Santa Cruz, CA; catalog number sc-40), FOXP3 (Abcam, ab20034
for IHC and ab450 for western blot, Cambridge, MA), hFOXY (eBioscience,
catalog number 14-5779-82 for western blot in HPEC), anti-V5 (Invitrogen,
SKU number R960-25), Ki67 (DakoCytomation, code numberM7249, Carpen-
teria, CA), b-actin (Sigma, catalog number A5441, St. Louis, MO), and anti-IgG
(Santa Cruz Biotechnology, Santa Cruz, CA).
Cancer Cell
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Because FOXP3 is expressed at lower levels in epithelial cells than in the regu-
latory T cells, the conditions typically used for detecting Treg cells in tumor
samples do not give reproducible staining in the epithelial cells. To facilitate
replication of the current studies, we have screened commercially available
anti-FOXP3 antibodies and established staining conditions that give strong
staining of FOXP3 in human and mouse epithelial cells.
The normal and cancer prostate frozen samples were partially thawed at
room temperature and then immersed in 10% formalin for 8–12 hr and
embedded in paraffin. Antigens were retrieved by microwave in 13 target
retrieval buffer (Dako) for 12 min. For TMA samples, antigens were retrieved
at 37C overnight after the microwave antigen retrieval treatment. ABC detec-
tion system was used for immunostaining according to the manufacturer’s
protocol (Vectastain Elite ABC, Burlingame, CA). The incubation time for
primary antibody FOXP3 (Abcam 236A/E7, 1:100), FoxP3 (BioLegend
Poly6238, 1:100), c-Myc (Santa Cruz Biotechnology 9E10, 1:200), c-Myc (Ab-
cam ab39688, 1:100), and Ki67 (Dako TEC-3, 1:100) was overnight at 4C.
After incubation with primary antibody, staining was followed by ABC detec-
tion system using biotinylated anti-mouse/rabbit/rat IgG. AEC was used as
chromogen. The slides were counterstained with hematoxylin and mounted
in xylene mounting medium for examination.
Statistical Analysis
The distribution of samples for each group was evaluated using a one-sample
Kolmogorov-Smirnov test. In the samples with normal distributions, we
compared the means of the dependent variable using a paired-samples
t test and means of the independent variable using an independent-samples
t test between two groups. In the samples with nonnormal distribution, we
compared the means of the independent variable between two groups using
a Mann-Whitney U test. Chi-square test was used to compare the relationship
between the expression of FOXP3 and MYC among patients. The relationship
between the levels of gene expression was estimated using a linear regression
model. All data were entered into an access database and analyzed using the
Excel 2000 and SPSS (version 10.0; SPSS, Inc.) software.
ACCESSION NUMBERS
The raw data for Figure S11 have been submitted to ArrayExpress under
accession number E-MTAB-108.
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